Concord Drugs (BOM:538965) 5-Year EBITDA Growth Rate : 1.70% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Concord Drugs 5-Year EBITDA Growth Rate?

Concord Drugs's EBITDA per Share for the three months ended in Dec. 2023 was ₹0.63.

During the past 12 months, Concord Drugs's average EBITDA Per Share Growth Rate was -1.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 8.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Concord Drugs was 18.90% per year. The lowest was -25.80% per year. And the median was 8.70% per year.

Competitive Comparison of Concord Drugs's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Concord Drugs's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Concord Drugs's 5-Year EBITDA Growth Rate falls into.

Concord Drugs 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Concord Drugs (BOM:538965) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Concord Drugs 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Concord Drugs's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Drugs (BOM:538965) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Concord Drugs Ltd (BOM:538965) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

3-11-451, L B Nagar, Hayatnagar Mandal, Hyderabad, TG, IND, 500074

Website

https://www.concorddrugs.in

Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers. Geographically, it operates only in India.

Concord Drugs (BOM:538965) Headlines

No Headlines